Trial Profile

Phase I Study of HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (HEROS 3.0)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CAR-T cell therapies (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
Indications Sarcoma
Focus Adverse reactions
Acronyms HEROS 3.0

Most Recent Events

14 Jan 2026 Planned End Date changed from 31 Dec 2040 to 30 Jun 2043.
14 Jan 2026 Planned primary completion date changed from 31 Dec 2027 to 30 Jun 2028.
23 Jan 2024 Planned End Date changed from 1 Feb 2040 to 31 Dec 2040.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com